Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

Abstract Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. M...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Panupong Hansrivijit, Wisit Cheungpasitporn, Charat Thongprayoon, Nasrollah Ghahramani
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMC 2020-04-01
Sarja:BMC Nephrology
Aiheet:
Rituximab
FSGS
Focal segmental glomerulosclerosis
MCD
Minimal change disease
Nephrotic syndrome
Linkit:http://link.springer.com/article/10.1186/s12882-020-01797-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia